Three bacteria—Ruminococcus, Collinsella, and Bifidobacterium—have been linked to DLB by experts at Nagoya University Graduate Medical School in Japan.
Alpha-synuclein, a protein in the brain that affects signal transmission between neurons, is connected to the development of dementia with lewy bodies. The "Lewy bodies" alter the brain's chemical processes, impairing memory, thinking, and reasoning. Some of the symptoms include confusion, difficulty moving, memory loss, and visual hallucinations.
Parkinson's disease also affects movements, although some people start to experience cognitive impairment after a year. When these people experience this cognitive impairment, DLB is diagnosed.
Those with DLB, eye blinking behavior disorder, and Parkinson's disease had their bile acids and gut microorganisms examined by Nagoya University Graduate Medical School researchers. They were directed by Professor Masaaki Hirayama, Assistant Professor Hiroshi Nishiwaki, and Associate Professor Kinji Ohno (all of whom specialise in omic medicine and neurogenetics) (Neurogenetics).
They found that patients with DLB were associated with three gut bacteria, Ruminococcus, Collinsella, and Bifidobacterium. This may point to potential diagnostic and therapeutic approaches for this neurodegenerative condition.
The study found some similarities inside the gut bacteria linked to Parkinson's disease and DLB. In both diseases, the intestinal mucosa degrading bacterium Akkermansia rose.
Also, researchers found similarities between Parkinson's illness and the gut bacteria linked to DLB. In both diseases, the intestinal mucosa-degrading bacterium Akkermansia multiplied. Ohno claims that people with ALS, Parkinson's disease, and Alzheimer's disease typically show declines in subset of fatty acids producing microbes. This suggests that it is a trait of numerous neurodegenerative diseases.
The researchers found that people with DLB had higher levels of Collinsella, lower levels of Bifidobacterium, and higher levels of Ruminococcus torques. This was not the case for those with Parkinson's disease, who saw a change in their levels.
The lower Bifidobacterium levels are significant since they may also indicate DLB therapy possibilities. Bifidobacterium upregulates a critical protein that aids in the growth, development, and maintenance of neurons in the central and peripheral nervous systems.
By reintroducing the abnormal bacteria that both DLB and Parkinson's disease share, it might be feasible to postpone their start. The first step in treating dementia is to improve the gut microbiome.
